Blood-Based Biomarkers for Neurodegeneration

Blood-Based Biomarkers for Neurodegeneration

Introduction

Blood Based Biomarkers For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Blood-based biomarkers have revolutionized the diagnosis and monitoring of [neurodegenerative diseases](/diseases), transforming what was once reliant on expensive PET imaging or invasive cerebrospinal fluid (CSF) collection into accessible, scalable clinical tools. [@bloodbased]
The development of ultrasensitive immunoassay platforms—including single-molecule array (Simoa), Meso Scale Discovery (MSD) electrochemiluminescence, and Lumipulse chemiluminescent enzyme immunoassay—has enabled reliable detection of brain-derived proteins in peripheral blood at femtomolar concentrations[@association] [@profiling]
. [@associationa]

...

Blood-Based Biomarkers for Neurodegeneration

Introduction

Blood Based Biomarkers For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Blood-based biomarkers have revolutionized the diagnosis and monitoring of [neurodegenerative diseases](/diseases), transforming what was once reliant on expensive PET imaging or invasive cerebrospinal fluid (CSF) collection into accessible, scalable clinical tools. [@bloodbased]
The development of ultrasensitive immunoassay platforms—including single-molecule array (Simoa), Meso Scale Discovery (MSD) electrochemiluminescence, and Lumipulse chemiluminescent enzyme immunoassay—has enabled reliable detection of brain-derived proteins in peripheral blood at femtomolar concentrations[@association] [@profiling]
. [@associationa]

The core panel of blood biomarkers for neurodegeneration includes phosphorylated [tau](/proteins/tau) (p-[tau](/proteins/tau) species (p-tau181, p-tau217, p-tau231), [Neurofilament light chain (NfL)](/biomarkers/neurofilament-light-chain-nfl))))))))))))))))))))))))))))))), [glial fibrillary acidic protein](/entities/glial-fibrillary-acidic-protein) ([GFAP](/entities/gfap)), and [Amyloid-Beta](/proteins/amyloid-beta) ratios ([Aβ42](/proteins/amyloid-beta)/40). These analytes reflect distinct pathological processes: amyloid plaque deposition, tau pathology], neuronal injury, and astrocytic reactivity. [@physically]
In May 2025, the FDA cleared the first blood test for [Alzheimer's disease](/diseases/alzheimers-disease) diagnosis—the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio—marking a landmark clinical milestone[@bloodbased]. [^6]

Blood biomarkers are now being integrated into updated diagnostic criteria for AD and are under active investigation for [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/als), [frontotemporal dementia](/diseases/frontotemporal-dementia), [Huntington's disease](/mechanisms/huntington-pathway), and other neurodegenerative conditions. [^7]

Comparison: Fluid vs Imaging Biomarkers

Blood-based biomarkers offer significant advantages over traditional imaging and cerebrospinal fluid approaches:

| Characteristic | Blood Biomarkers | CSF Biomarkers | PET Imaging |
|----------------|------------------|----------------|-------------|
| Invasiveness | Minimal (blood draw) | High (lumbar puncture) | None |
| Cost | $200-500 | $300-600 | $3,000-5,000 |
| Accessibility | Widely available | Specialty labs | Limited centers |
| Time to result | Days | Days-Weeks | Days-Weeks |
| Repeatability | Excellent | Good | Limited |
| Amyloid detection | Good (p-tau217 Aβ42/40) | Excellent | Excellent |
| Tau detection | Good (p-tau217/181) | Excellent | Excellent |
| Neurodegeneration | Good (NfL) | Good | Moderate |

Key advantages of blood biomarkers:

• Enable population-based screening and primary care screening
• Dramatically reduce clinical trial screening失败率 (failure rate)
• Allow frequent monitoring for disease progression and treatment response
• More accessible for diverse and rural populations
• Cost-effective for healthcare systems

Limitations compared to imaging:

• Cannot provide spatial information about amyloid/tau load
• Less established for some rare neurodegenerative conditions

-仍在建立标准化参考范围

The FDA clearance of the Lumipulse G pTau217 test in May 2025 represents a paradigm shift, validating blood-based biomarkers as equivalent to PET imaging for diagnostic confirmation in Alzheimer's disease.

Clinical Utility and Trial Enrichment

Blood biomarkers are transforming clinical trial design and patient selection:

Trial Enrichment Strategies

• Pre-screening: Blood tests can pre-screen participants for amyloidpositivity, reducing the need for expensive PET scans in screening phases
• Stratification: Biomarker levels (p-tau217, NfL) can stratify patients by disease stage and expected progression rate
• Endpoint biomarkers: P-tau217 and NfL are being validated as surrogate endpoints for clinical trials

Anti-Amyloid Therapy Eligibility

For patients being considered for [lecanemab](/therapeutics/lecanemab) or [donanemab](/therapeutics/donanemab):

• Blood biomarkers can determine amyloid positivity without PET scan
• Reduces diagnostic costs from $5,000+ (PET) to ~$300 (blood test)
• Improves patient access, especially in rural and underserved areas

Cost-Effectiveness

• A blood-based screening paradigm could reduce AD diagnostic costs by up to 70%
• Enables earlier detection in primary care
• Insurance coverage expanding: Medicare covers FDA-cleared p-tau217 test

Core Blood Biomarkers

Phosphorylated Tau Species

Phosphorylated tau (p-tau biomarkers are highly specific for Alzheimer's Disease pathology and reflect active tau hyperphosphorylation] and secretion from [neurons](/entities/neurons): [^8]

P-tau217

P-tau217 has emerged as the most accurate single blood biomarker for AD diagnosis: [^9]

• Pathological specificity: P-tau217 levels begin rising 15-20 years before symptom onset, coinciding with early amyloid plaque formation and preceding tau PET positivity.

It reflects both amyloid and tau pathological changes[@profiling] [^10]
. [@parra2026]

• Diagnostic performance: Plasma p-tau217 detects AD pathology with area under the receiver operating characteristic curve (AUC) values of 0.93-0.96, with accuracies of 89-91%, positive predictive values of 89-95%, and negative predictive values of 77-90%[@associationa]

. [^12]

• FDA-cleared test: The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio was FDA-cleared on May 16, 2025 for use in adults aged 55 and older with cognitive symptoms.

In validation studies, 91.7% of individuals with positive plasma results had confirmed amyloid plaques by PET or CSF, and 97.3% of individuals with negative results had negative amyloid PET[@bloodbased]. [@aisen2025]

• Disease stratification: P-tau217 effectively differentiates between various Braak stages of tau pathology] and can distinguish AD from behavioral variant [FTD](/diseases/ftd) with 96% accuracy and from primary psychiatric disorders with 93% accuracy[@physically]

. [@aisen2025a]

• Clinical trial endpoint: P-tau217 is being evaluated as a surrogate endpoint in AD clinical trials, potentially enabling faster and cheaper drug development[^6].

P-tau181

• Earlier availability: P-tau181 was the first plasma p-tau species validated for clinical research and remains widely used.
• Amyloid correlation: Plasma p-tau181 correlates strongly with amyloid PET positivity and CSF p-tau181 levels.
• Predictive value: Elevated baseline p-tau181 is associated with significantly increased hazard for all-cause dementia (HR 1.5-2.5) over 10-year follow-up[@association].
• Limitation: Slightly lower diagnostic accuracy compared to [p-tau217](/biomarkers/p-tau-217), particularly in early disease stages.

P-tau231

• Early change: P-tau231 may be the earliest tau biomarker to change, rising even before amyloid PET positivity in some studies.
• Utility: Useful for detecting the earliest biological changes of AD, potentially before p-tau181 or p-tau217 become abnormal.

Neurofilament Light Chain

[Neurofilament light chain (NfL)](/biomarkers/neurofilament-light-chain-nfl))))))))))))))))))))))))))))))) is a structural cytoskeletal protein released into the extracellular space upon neuronal damage or degeneration: [@petersen2026]

• Non-specific neurodegeneration marker: Unlike p-tau, [NfL](/proteins/nfl-protein)) is elevated across virtually all neurodegenerative diseases and reflects the rate and degree of active neuronal injury rather than a specific proteinopathy[^7]

. [@arslan2026]

• Disease-specific patterns:
• [Alzheimer's disease](/diseases/alzheimers-disease): Elevated in prodromal and clinical AD; associated with hippocampal atrophy and cognitive decline. Higher [NfL](/proteins/nfl-protein) predicts faster progression.
• [ALS](/diseases/als): Markedly elevated (often 5-10× normal); one of the most reliable diagnostic and prognostic biomarkers for ALS. [NfL](/genes/nfl) levels correlate with disease progression rate and survival[^8].
• [frontotemporal dementia](/diseases/frontotemporal-dementia): Elevated in both behavioral variant FTD and [primary progressive aphasia](/diseases/primary-progressive-aphasia). NfL combined with p-tau can help distinguish FTD from AD.
• [Parkinson's disease](/diseases/parkinsons-disease): Blood NfL is typically normal in early PD but elevated in atypical parkinsonism ([MSA](/diseases/msa-genetic-variants), [PSP](/diseases/psp), [CBD), making it useful for differential diagnosis[^9]

. [@zheng2026]

• [Huntington's disease](/mechanisms/huntington-pathway): NfL rises years before motor symptom onset in HD gene carriers and tracks with clinical progression.
• [multiple sclerosis](/diseases/multiple-sclerosis): Reflects acute axonal damage during relapses and chronic neurodegeneration.
• Monitoring therapy: NfL is increasingly used as a pharmacodynamic biomarker in clinical trials—effective therapies should reduce NfL levels, indicating reduced neuronal damage[^7]

. [@titeca2026]

• Limitations: Elevated by non-neurodegenerative conditions including stroke, traumatic brain injury, peripheral neuropathy, and normal aging. Age-adjusted reference ranges are essential.

Glial Fibrillary Acidic Protein

[GFAP](/entities/glial-fibrillary-acidic-protein) is an intermediate filament protein primarily expressed by [astrocytes](/cell-types/astrocytes) and released into the bloodstream during [reactive astrogliosis](/mechanisms/reactive-astrogliosis): [@yeo2026]

• Astrocytic reactivity marker: Plasma GFAP reflects the degree of astrocytic activation and neuroinflammatory response in the brain[^10]

. [@kong2026]

• Alzheimer's specificity: Unlike NfL, plasma GFAP shows relative specificity for AD-type pathology. Elevated GFAP levels in cognitively unimpaired individuals predict future cognitive decline and amyloid positivity.
• Tau progression: Elevated plasma GFAP consistently contributes to [amyloid-beta](/proteins/amyloid-beta)-induced tau] progression across various Braak stages, suggesting that astrocytic reactivity mediates the link between amyloid and tau pathology[@profiling]

. [@janelidze2026]

• Differential diagnosis: Serum GFAP has better diagnostic efficacy than NfL for distinguishing AD from [mild cognitive impairment](/diseases/mci) and healthy controls[^10]

. [@mavridis2026]

• Combined use: GFAP combined with p-tau217 and NfL provides the highest diagnostic accuracy for AD.

Amyloid-Beta Ratio

• Aβ42/Aβ40 plasma ratio: A decreased Aβ42/40 ratio in plasma reflects preferential sequestration of Aβ42 into amyloid plaques in the brain, reducing its concentration in blood[@association].
• [amyloid PET](/entities/amyloid-pet) concordance: The plasma Aβ42/40 ratio shows moderate concordance with amyloid PET status (AUC 0.80-0.88), lower than p-tau217 alone.
• Combined biomarker: The Lumipulse G FDA-cleared test uses the pTau217/Aβ42 ratio for optimal diagnostic accuracy.
• Limitations: Plasma amyloid ratios are influenced by peripheral [Aβ](/proteins/amyloid-beta-protein) production (e.g., platelets), kidney function, and blood collection/processing conditions, making standardization challenging.

Available Clinical Tests

FDA-Cleared Tests

• Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio (Fujirebio/Labcorp): FDA-cleared May 2025. [Fully automated chemiluminescent enzyme immunoassay. For adults ≥55 with cognitive symptoms.

Positive predictive value 91.7%, negative predictive value 97.3% for amyloid PET concordance[@bloodbased]. [@rizvi2026]

Laboratory-Developed Tests

• PrecivityAD (C2N Diagnostics): Measures plasma p-tau217 and Aβ42/40 ratio using mass spectrometry. Available as a CLIA-certified lab test since 2020.
• ALZpath Dx (ALZpath): Measures plasma p-tau217 using Simoa technology. Designed for primary care and memory clinic settings.
• PrecivityAD2 (C2N Diagnostics): Second-generation test combining p-tau217 with additional analytes for improved accuracy[@associationa].

Applications Across Neurodegenerative Diseases

Alzheimer's Disease Diagnosis

Blood biomarkers are reshaping AD diagnostic paradigms: [@sperling2026]

• Primary care screening: P-tau217-based tests can identify amyloid-positive individuals in primary care settings with high accuracy, enabling earlier specialist referral[@associationa].
• Anti-amyloid therapy eligibility: For patients being considered for [anti-amyloid therapeutics](/mechanisms/anti-amyloid-therapeutics) ([lecanemab](/therapeutics/lecanemab), donanemab), blood biomarkers can replace or reduce the need for amyloid PET scans, improving access and reducing costs.
• Clinical trial recruitment: Blood screening dramatically accelerates clinical trial enrollment by pre-selecting amyloid-positive participants.
• Progression monitoring: Serial p-tau217 and NfL measurements can track disease progression and treatment response.

Differential Diagnosis

Blood biomarker panels help distinguish between neurodegenerative conditions: [@jucker2026]

| Biomarker | AD | FTD | PD | ALS | DLB | [@cnovas2026]
|-----------|-----|-----|-----|-----|-----| [@choo2026]
| P-tau217 | ↑↑↑ | Normal | Normal | Normal | ↑ | [@holtzman2026]
| NfL | ↑ | ↑↑ | Normal/↑ | ↑↑↑ | ↑ | [@honig2026]
| GFAP | ↑↑ | ↑ | Normal | ↑ | ↑ | [@honig2026a]
| Aβ42/40 | ↓↓ | Normal | Normal | Normal | ↓ | [@zetterberg2026]

• **AD vs.

FTD**: P-tau217 is markedly elevated in AD but normal in most FTD cases, enabling differentiation with >90% accuracy[@physically].

• **PD vs.

atypical parkinsonism**: NfL distinguishes typical PD (normal levels) from [MSA](/diseases/msa-genetic-variants), [PSP](/diseases/psp), and [CBD](/diseases/corticobasal-degeneration) (elevated levels)[^9].

• Dementia with Lewy bodies: DLB patients may have elevated p-tau217 due to co-occurring AD pathology; the combination of p-tau217 with [alpha-synuclein](/proteins/alpha-synuclein) seed amplification assays (SAA) is under investigation.

Parkinson's Disease

• alpha-synuclein SAA: Seed amplification assays for [alpha-synuclein](/proteins/alpha-synuclein) in CSF and blood are emerging as disease-specific biomarkers for synucleinopathies, complementing NfL and GFAP[^9]

.

• Progression tracking: In PD, NfL emerged as the best predictor of motor and cognitive progression, with marginal effects of GFAP and p-tau181.

ALS

• Diagnosis: Plasma NfL is markedly elevated in [ALS](/diseases/als) and can support early diagnosis, particularly in distinguishing ALS from ALS mimics.
• Prognosis: Higher NfL at baseline predicts faster functional decline and shorter survival.
• Drug development: NfL reduction is a key pharmacodynamic endpoint in ALS clinical trials (e.g., tofersen for SOD1-ALS).

Predictive and Preclinical Detection

• Community-based screening: In the Framingham Heart Study and other large cohorts, elevated baseline p-tau181, p-tau217, NfL, and GFAP predicted incident all-cause dementia and AD dementia over 10-year follow-up, with AUCs of 70.9-82.6%[@association]

.

• Preclinical AD: Blood biomarkers can identify amyloid-positive, cognitively unimpaired individuals—the target population for prevention trials.
• Risk stratification: Multi-analyte panels combining p-tau217, GFAP, NfL, and Aβ42/40 provide the most accurate risk stratification for future cognitive decline.

Challenges and Future Directions

Technical Challenges

• Pre-analytical variability: Blood collection tubes, processing time, hemolysis, and storage conditions can affect biomarker measurements.

Standardization of pre-analytical procedures is essential[@parra2026].

• Platform harmonization: Different assay platforms (Simoa, Lumipulse, MSD, mass spectrometry) yield different absolute values for the same analytes. Universal cut-off values remain elusive.
• Confounders: Age, sex, body mass index, kidney function, and comorbidities influence blood biomarker levels and must be accounted for in clinical interpretation.

Emerging Biomarkers

• P-tau205: A novel phospho-tau species that may more closely reflect tau tangle load rather than amyloid-associated tau secretion.
• Brain-derived tau (BD-tau: A fragment specific to brain-derived tau, potentially more specific than total tau for neurodegeneration[@parra2026].
• MTBR-tau243: A microtubule-binding region fragment of tau that correlates with tau PET signal and cognitive decline.
• alpha-synuclein SAA in blood: Seed amplification assays for alpha-synuclein are being adapted from CSF to blood, which would transform synucleinopathy diagnosis.
• [TDP-43](/proteins/tdp-43) biomarkers: Actively sought for [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) (ALS, FTD-TDP, [LATE](/diseases/late) but not yet available.

Health Equity Considerations

• Accessibility: Blood tests are far more accessible and affordable than PET imaging or lumbar puncture, potentially democratizing AD diagnosis across socioeconomic and geographic barriers.
• Diverse populations: Most biomarker validation studies have been conducted in predominantly White European populations.

Validation in diverse populations is critical, as [APOE](/proteins/apoe-protein) genotype frequencies and comorbidity profiles differ across ancestry groups[@parra2026].

• Primary care integration: Implementing blood biomarker testing in primary care requires clinician education, standardized reporting, and clear diagnostic algorithms.

External Links

• [Alzheimer's Association Blood Test Information](https://www.alz.org/news/2025/fda-clears-blood-test-alzheimers-diagnosis)
• [Labcorp Lumipulse Test](https://ir.labcorp.com/news-releases/news-release-details/labcorp-launches-first-fda-cleared-blood-test-alzheimers-disease)
• [PrecivityAD - C2N Diagnostics](https://precivityad.com/)
• [NfL as a Biomarker - Practical Neurology](https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/neurofilament-light-as-a-dementia-biomarker/31732/)

See Also

• [astrocytes](/cell-types/astrocytes)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [tau protein](/proteins/tau)
• [Amyloid-Beta Aggregation](/mechanisms/amyloid-aggregation)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/als)
• [Huntington's Disease](/mechanisms/huntington-pathway)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [neuroinflammation](/mechanisms/neuroinflammation)

Recent Research (2025-2026)

Recent 2026 studies reinforce that [blood-based biomarkers](/mechanisms/blood-based-biomarkers) integrate metabolic, vascular, and proteomic signals that improve early [Alzheimer's Disease](/diseases/alzheimers-disease) stratification when interpreted in clinical context.

• 2026: [Biological age acceleration associates with Alzheimer's Disease plasma biomarker levels](https://pubmed.ncbi.nlm.nih.gov/41572665/) indicates that biological aging context can shift interpretation of plasma AD markers.[@honig2026]
• 2026: [Lysophosphatidylcholines are associated with amyloidosis in early stages of Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/41407938/) supports lipidomic features as complementary blood signals for early amyloid-related change.[@honig2026a]
• 2026: [Vascular stiffness predicts plasma markers of neurodegeneration among older African Americans](https://pubmed.ncbi.nlm.nih.gov/41763008/) shows vascular state can modulate biomarker distributions, motivating calibration-aware deployment.[@zetterberg2026]

Background

The study of Blood Based Biomarkers For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• [The association between temporal-lobe tensor-based morphometry and plasma amyloid-β in mild cognitive impairment.](https://pubmed.ncbi.nlm.nih.gov/41724104/) (2026 May) - Clinical neurology and neurosurgery
• [Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration.](https://pubmed.ncbi.nlm.nih.gov/41667028/) (2026 May) - Ageing research reviews
• [Profiling mitochondrial DNA indices across whole blood, plasma, and CSF in amyotrophic lateral sclerosis.](https://pubmed.ncbi.nlm.nih.gov/41740345/) (2026 Apr 15) - Journal of the neurological sciences
• [Association between sleep duration and fluid biomarkers of Alzheimer's disease: A systematic review.](https://pubmed.ncbi.nlm.nih.gov/41610733/) (2026 Apr) - Sleep medicine reviews
• [A physically and mentally active lifestyle relates to younger brain and cognitive age.](https://pubmed.ncbi.nlm.nih.gov/40619559/) (2026 Apr) - GeroScience

Pathway Diagram

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unkaisen2025a]: [Aisen et al., Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's Disease (2025)](https://pubmed.ncbi.nlm.nih.gov/40990131/)

[@petersen2026]: [Petersen et al., Predicting onset of symptomatic Alzheimer's Disease with plasma p-tau217 clocks (2026)](https://pubmed.ncbi.nlm.nih.gov/41714746/)
[@arslan2026]: [Arslan et al., Comparative analysis of plasma p-tau217 immunoassays: challenges for standardization and harmonization (2026)](https://pubmed.ncbi.nlm.nih.gov/41202177/)
[@zheng2026]: [Zheng et al., Targeted blood proteome profiling using NULISAseq identifies a high-performance biomarker panel for A-beta pathology quantification and staging (2026)](https://pubmed.ncbi.nlm.nih.gov/41612914/)
[@titeca2026]: [Titeca et al., Automated high-throughput quantification of plasma p-tau217 and APOE-e4 for Alzheimer's Disease diagnosis and cognitive decline in a memory cohort (2026)](https://pubmed.ncbi.nlm.nih.gov/41764587/)
[@yeo2026]: [Yeo et al., Visuospatial memory deficit, plasma p-tau217, and A-beta42/A-beta40 ratio enhance sensitivity to identify A-beta PET positivity in individuals with SCD (2026)](https://pubmed.ncbi.nlm.nih.gov/41763100/)
[@kong2026]: [Kong et al., Diagnostic and prognostic utility of serum beta-synuclein in Alzheimer's Disease: a longitudinal cohort study (2026)](https://pubmed.ncbi.nlm.nih.gov/41763014/)
[@janelidze2026]: [Janelidze et al., Diagnostic Value of Serum p-tau217 in Alzheimer's Disease: Equal to Plasma in Levels and Clinical Utility? (2026)](https://pubmed.ncbi.nlm.nih.gov/41231544/)
[@mavridis2026]: [Mavridis et al., Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia (2026)](https://pubmed.ncbi.nlm.nih.gov/41627837/)
[@rizvi2026]: [Rizvi et al., Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adults (2026)](https://pubmed.ncbi.nlm.nih.gov/41724695/)
[@sperling2026]: [Sperling et al., The prognostic value of blood-based p-tau217 levels on progression to clinical impairment (2026)](https://pubmed.ncbi.nlm.nih.gov/41728293/)
[@jucker2026]: [Jucker et al., Plasma levels of an N-terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's Disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41505233/)
[@cnovas2026]: [Cánovas et al., When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ-PET Centiloid 15, Mean Age of 66 Years (2026)](https://pubmed.ncbi.nlm.nih.gov/41586468/)
[@choo2026]: [Choo et al., Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer's Disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41763013/)
[@holtzman2026]: [Holtzman et al., Analyses of plasma multi-omic data across ancestries identify novel pathways implicated in Alzheimer's Disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41653107/)
[@honig2026]: [Honig et al., Biological age acceleration associates with Alzheimer's Disease plasma biomarker levels (2026)](https://pubmed.ncbi.nlm.nih.gov/41572665/)
[@honig2026a]: [Honig et al., Lysophosphatidylcholines are associated with amyloidosis in early stages of Alzheimer's Disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41407938/)
[@zetterberg2026]: [Zetterberg et al., Vascular stiffness predicts plasma markers of neurodegeneration among older African Americans (2026)](https://pubmed.ncbi.nlm.nih.gov/41763008/)---

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 31 references |
| Replication | 33% |
| Effect Sizes | 75% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |

Overall Confidence: 56%

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
• [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
• [Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: FCGRT
• [Circadian-Synchronized LRP1 Pathway Activation](/hypothesis/h-7e0b5ade) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: LRP1, MTNR1A, MTNR1B
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Magnetosonic-Triggered Transferrin Receptor Clustering](/hypothesis/h-aa2d317c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFR1
• [Piezoelectric Nanochannel BBB Disruption](/hypothesis/h-7a8d7379) — <span style="color:#ff8a65;font-weight:600">0.40</span> · Target: CLDN5, OCLN

Related Analyses:

• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;